Physician profile
Alexander Menning
NPI 1700306636
$8,180.42
in general payments reported to CMS, 2019-2025
17 companies · $837 in 2025
The $837 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $111 · 2022: $1,279 · 2023: $1,101 · 2024: $4,744 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,500 · Food and Beverage: $1,208 · Travel and Lodging: $974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,500.00 |
| Food and Beverage | $1,207.92 |
| Travel and Lodging | $973.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $7,048.58 | 2022-2025 | Davinci Xi |
| Medtronic, INC. | $154.92 | 2025 | Signia |
| Zimmer Biomet Holdings, INC. | $111.02 | 2020 | |
| Kci USA, INC. | $108.38 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $106.25 | 2024 | Zeposia |
| Olympus Corporation of The Americas | $100.99 | 2023 | Evis Exera Lll Colonovideoscope |
| Janssen Biotech, INC. | $96.14 | 2024-2025 | Tremfya |
| Lumendi LLC | $92.55 | 2025 | |
| Lilly USA, LLC | $82.56 | 2024-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $82.06 | 2024-2025 | Entyvio, Eohilia |
| Abbvie INC. | $35.88 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $35.55 | 2024-2025 | Dupixent |
| Celltrion USA INC. | $33.75 | 2025 | Vegzelma |
| Aimmune Therapeutics, INC. | $28.69 | 2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $28.45 | 2024-2025 | Voquezna |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $17.92 | 2025 | Rezdiffra |
| Genzyme Corporation | $16.73 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Menning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.